Cabaletta Bio to Take Part in Upcoming Investor Conferences
Cabaletta Bio, Inc. (NASDAQ: CABA), a clinical-stage biotechnology firm dedicated to developing targeted cell therapies for patients suffering from autoimmune diseases, is gearing up to participate in several prominent investor conferences this September. These events will offer stakeholders a chance to gain insights into the company's mission and innovations.
Conference Schedule
Here are the upcoming investor conferences where Cabaletta Bio will be featured:
Morgan Stanley 22nd Annual Global Healthcare Conference
During this conference, Cabaletta will engage in a fireside chat on Wednesday, where they will provide an overview of their recent advancements and strategic plans.
2024 Wells Fargo Healthcare Conference
On Thursday, representatives from the company will share their innovative strategies in a fireside chat, offering insights into their research and the therapeutic potential of their pipeline.
H.C. Wainwright 26th Annual Global Investment Conference
Another significant session is scheduled for Wednesday, where Cabaletta will showcase its clinical progress and future projections.
2024 Cantor Fitzgerald Global Healthcare Conference
On Tuesday, the final engagement for September will be a fireside chat, during which Cabaletta will discuss its ongoing projects and their importance in the biotechnology sector.
Webcast Information
Investors and interested individuals can tune in to live webcasts of each presentation through the News and Events section of Cabaletta Bio’s website. Additionally, recordings of these presentations will be available for 30 days after the events, allowing for wider audience participation.
About Cabaletta Bio
Cabaletta Bio is leading the charge in developing engineered T cell therapies aimed at delivering potentially curative treatments for autoimmune diseases. Their proprietary CABA™ platform features two primary strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody receptor T cells).
The flagship product under the CARTA strategy is CABA-201, which is currently being evaluated in multiple clinical studies, including the RESET™ clinical trials that target conditions such as myositis, systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. In addition, the CAART strategy includes candidates like DSG3-CAART for mucosal pemphigus vulgaris and MuSK-CAART for MuSK-associated myasthenia gravis.
Cabaletta Bio is committed to advancing its innovative therapies, with the goal of providing long-lasting responses for patients facing a variety of autoimmune disorders. The company is headquartered in Philadelphia, where it also operates state-of-the-art laboratories.
Contacts
Anup Marda
Chief Financial Officer
investors@cabalettabio.com
William Gramig
Precision AQ
william.gramig@precisionaq.com
Frequently Asked Questions
What is the main focus of Cabaletta Bio?
Cabaletta Bio focuses on developing targeted cell therapies that aim to provide curative solutions for patients with autoimmune diseases.
Which investor conferences will Cabaletta Bio attend?
The company will participate in the Morgan Stanley Global Healthcare Conference, Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, and Cantor Fitzgerald Global Healthcare Conference.
How can one view the webcasts of the presentations?
Live webcasts of the presentations will be available on Cabaletta Bio’s website under the News and Events section, and replays will be accessible for 30 days after the events.
What are the key strategies within Cabaletta Bio's CABA™ platform?
The CABA™ platform includes CARTA for chimeric antigen receptor T cells and CAART for chimeric autoantibody receptor T cells, targeting various autoimmune conditions.
Where is Cabaletta Bio headquartered?
Cabaletta Bio is headquartered in Philadelphia, PA, where it operates its laboratories and main office.